a phase II study of chemotadiotherapy for 80 or more year-old patients with esophageal cancer

a phase II study of chemotadiotherapy for 80 or more year-old patients with esophageal cancer - a phase II study of chemotadiotherapy for elder patients with esophageal cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031437

Enrollment

Registered

2018-03-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

radiotherapy with 60 Gy/ 30fractions and chemotherapy (CDGP+5-FU)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. histologically proved esophageal cancer 2. T1-4, N0-3, M0/1 lym (UICC 2009) 3. 80 or more years old 4. Performance Status(ECOG):0-1 5. without other severe disease

Exclusion criteria

Exclusion criteria: 1. with distant organ metastases 2. with past irradiation history around current tumors 3. with past history of ESD or EMR for esophageal cancer 4. with active other malignancy 5. with severe other disease

Design outcomes

Primary

Measure	Time frame
completion rate of chemoradiotherapy	—

Secondary

Measure	Time frame
overall survival rate, progression-free survial rate and toxicities	—

Countries

Japan

Contacts

Public ContactKeiichi Jingu

see above see above

kjingu-jr@rad.med.tohoku.ac.jp022-717-7312

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026